Full Press Release Details
Announces Consensi Commercialization Agreement for China
to receive milestone payments of up to $9.5 million, as well as potential double-digit royalties
PDUFA date of May 31, 2018, Upcoming
AVIV, Israel, May 11, 2018 / GlobeNewsWire/ --
Pharma Ltd. (NASDAQ: KTOV; TASE: KTOV), an innovative biopharmaceutical company, announced today that the Company has signed a
definitive license and commercialization agreement for the Chinese market, granting exclusive rights to import, manufacture and
distribute its lead drug candidate, Consensi , in China to Hebei Changshan Biochemical Pharmaceutical Co., Ltd. (Changshan
Pharma), a Chinese public company traded on the Shenzhen Stock Exchange.
known as KIT-302, is a combination drug intended to simultaneously treat pain caused by osteoarthritis, and hypertension, which
is a common side effect of stand-alone drugs that treat osteoarthritis pain. Consensi is comprised of two FDA-approved drugs,
celecoxib (Celebrex ), a non-steroidal anti-inflammatory COX-2 inhibitor (NSAID) for the treatment of pain caused by osteoarthritis,
and amlodipine besylate (Norvasc ), a calcium channel blocker for lowering blood pressure.
Upon receipt of marketing
authorization in China, Changshan Pharma will have the exclusive right and license to import, manufacture, distribute, and sell
Consensi in China, Taiwan, Hong Kong, and Macao. Changshan Pharma will be responsible for financing and seeking regulatory
approval for Consensi in China. Under the terms of the agreement, Kitov is entitled to receive up to an aggregate of $3.5
million for U.S. FDA approval of Consensi , which has a PDUFA date of May 31, 2018, and for China regulatory milestones;
up to an aggregate of $6.0 million for predefined commercial milestones; and up to 12% royalties on net sales.
pleased to enter into this commercialization agreement for Consensi and look forward to building a long-term relationship
with Changshan Pharma in China. Changshan Pharma has a strong track record of successfully launching and marketing pharmaceutical
products in China," said Dr. Gil Ben-Menachem, Kitov's Vice President - Business Development. "This is the second commercialization
agreement for Consensi in Asia, further confirming its global sales potential. Kitov continues to work diligently towards
finalizing additional commercialization agreements in the U.S. and in other territories."
Consensi has substantial commercial potential in China and will provide significant benefit to Chinese patients. We are
well-positioned to maximize the value of this product in the Chinese market, and look forward to seeking regulatory approval and
launching Consensi in China," said Mr. Shuhua Gao, Chairman and General Manager of Changshan Pharma.
The total annual NSAID market in China is estimated at hundreds of millions of dollars, according to
IMS. Moreover, celecoxib sales in China represented 25% of the total NSAID market. In recent years, sales of selective COX-2 inhibitors
(coxibs), and especially Celebrex (Pfizer's
branded celecoxib), have been increasing in China at an annual rate of 25 percent.
Pharma (Kitov Pharma Ltd.; NASDAQ/TASE: KTOV) is an innovative biopharmaceutical drug development group of companies. Leveraging
deep regulatory and clinical-trial expertise, Kitov's veteran team of healthcare and business professionals maintains a proven
track record in streamlined end-to-end drug development and approval. Kitov's flagship combination drug, Consensi , intended
to treat osteoarthritis pain and hypertension simultaneously, achieved the primary efficacy endpoints for its Phase III and Phase
III/IV clinical trials. NT219, which is developed by its majority-owned subsidiary, TyrNovo Ltd., is a novel patented small molecule
designed to overcome cancer drug resistance that is currently in pre-clinical development. By lowering development risk and cost
through fast-track regulatory approval of novel late-stage therapeutics, Kitov plans to deliver rapid ROI and long-term potential
to investors, while making a meaningful impact on people's lives. For more information on Kitov, the content of which is not part
of this press release, please visit http://www.kitovpharma.com.
Changshan Biochemical Pharmaceutical Co., Ltd. (Changshan Pharma) is a fully-integrated, publicly-traded (stock code: 300255)
pharmaceutical company with headquarters in Shijiazhuang, Hebei, China. Changshan Pharma is a leading supplier of Heparin and
Low Molecular Weight Heparin pharmaceutical products from its state-of-the-art manufacturing facilities. Changshan Pharma has
a long history of international collaborations leading to a deep and diverse pipeline of innovative products across various therapeutic
categories and dosage forms.
Statements and Kitov's Safe Harbor Statement
statements in this press release are forward-looking statements within the meaning of the safe harbor provisions of the Private
Securities Litigation Reform Act of 1995 and other applicable securities laws. Forward-looking statements can be identified by
the use of forward-looking words such as "believe", "expect", "intend", "plan", "may",
"should", "could", "might", "seek", "target", "will", "project",
"forecast", "continue" or "anticipate" or their negatives or variations of these words or other
comparable words or by the fact that these statements do not relate strictly to historical matters. You should not place undue
reliance on these forward-looking statements, which are not guarantees of future performance. Forward-looking statements reflect
our current views, expectations, beliefs or intentions with respect to future events, and are subject to a number of assumptions,
involve known and unknown risks, many of which are beyond our control, as well as uncertainties and other factors that may cause
our actual results, performance or achievements to be significantly different from any future results, performance or achievements
expressed or implied by the forward-looking statements. Important factors that could cause or contribute to such differences include,
among others, risks relating to: the fact that drug development and commercialization involves a lengthy and expensive process
with uncertain outcomes; our ability to successfully develop and commercialize our pharmaceutical products; the expense, length,
progress and results of any clinical trials; the lack of sufficient funding to finance the clinical trials; the impact of any
changes in regulation and legislation that could affect the pharmaceutical industry; the difficulty in receiving the regulatory
approvals necessary in order to commercialize our products; the difficulty of predicting actions of the U.S. Food and Drug Administration
or any other applicable regulator of pharmaceutical products; the regulatory environment and changes in the health policies and
regimes in the countries in which we operate; the uncertainty surrounding the actual market reception to our pharmaceutical products
once cleared for marketing in a particular market; the introduction of competing products; patents attained by competitors; dependence
on the effectiveness of our patents and other protections for innovative products; our ability to obtain, maintain and defend
issued patents with protective claims; the commencement of any patent interference or infringement action; our ability to prevail,
obtain a favorable decision or recover damages in any such action; and the exposure to litigation, including patent litigation,
and/or regulatory actions; the uncertainty surrounding an investigation by the Israel Securities Authority into our historical
public disclosures and the potential impact of such investigation on the trading of our securities or on our clinical, commercial
and other business relationships, or on receiving the regulatory approvals necessary in order to commercialize our products, and
other factors that are discussed in our in our Annual Report on Form 20-F for the year ended December 31, 2017 and in
our other filings with the SEC, including our cautionary discussion of risks and uncertainties under Risk Factors' in our Registration
Statements and Annual Reports. These are factors that we believe could cause our actual results to differ materially from expected
results. Other factors besides those we have listed could also adversely affect us. Any forward-looking statement in this press
release speaks only as of the date which it is made. We disclaim any intention or obligation to publicly update or revise any
forward-looking statement, or other information contained herein, whether as a result of new information, future events or otherwise,
except as required by applicable law. You are advised, however, to consult any additional disclosures we make in our reports to
the SEC, which are available on the SEC's website, http://www.sec.gov
further information, contact:
Chief Financial Officer of Kitov and Director of TyrNovo
+972-3-933-3121 ext. #105
LifeSci Advisors, LLC